|
|
非奈利酮在糖尿病肾病患者中的应用研究进展
|
Abstract:
糖尿病肾病(diabetic kidney disease, DKD)是一种常见的糖尿病并发症，若未在糖尿病肾病早期临床阶段对其进行控制，则该病将进展为终末期肾病(end-stage renal disease, ESRD)。为提高患者的生活质量，降低糖尿病肾病患者的死亡率，药物选择就尤为关键。新型盐皮质激素受体拮抗剂(mineralocorticoid receptor antagonist, MRA)非奈利酮以其高选择性、有效阻断盐皮质激素受体，能有效地保护心、肾，为目前治疗糖尿病肾病的一个新的选择。本文旨在通过分析糖尿病肾病的主要发病机制以及非奈利酮的药理机制、临床应用等方面内容，为后续糖尿病肾病患者应用此药治疗提供一定临床依据。
Chronic kidney disease (DKD) is a common complication of diabetes. If it is not controlled in the early clinical stage, it will develop into end-stage renal disease (ESRD). In order to improve the quality of life of patients and reduce the mortality of patients with diabetes nephropathy, drug se-lection is particularly critical. The new mineralocorticoid receptor antagonist, finerenone, with its high selectivity and effective blocking of mineralocorticoid receptor, can effectively protect the heart and kidney, and is a new choice for the treatment of diabetes nephropathy. The purpose of this article is to provide some clinical basis for the follow-up treatment of diabetes nephropathy by analyzing the main pathogenesis, pharmacological mechanism and clinical application of finere-none.
| [1] | Koro, C.E., Bo, H.L. and Bowlin, S.J. (2009) Antidiabetic Medication Use and Prevalence of Chronic Kidney Disease among Patients with Type 2 Diabetes Mellitus in the United States. Clinical Therapeutics, 31, 2608-2617.
https://doi.org/10.1016/j.clinthera.2009.10.020 |
| [2] | Alicic, R.Z., Rooney, M.T. and Tuttle, K.R. (2017) Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clinical Journal of the American Society of Nephrology, 12, 2032-2045.
https://doi.org/10.2215/CJN.11491116 |
| [3] | Jankowski, J., Floege, J., Fliser, D., et al. (2021) Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. Circulation, 143, 1157-1172.
https://doi.org/10.1161/CIRCULATIONAHA.120.050686 |
| [4] | Agodoa, L. (2000) United States Renal Data System (USRDS). Nefrologia, 20, 13-16. |
| [5] | Saez, M., Vizcaya, D., Vizcaya, D., et al. (2021) Incidence and Risk Factors for Mortality and End-Stage Renal Disease in People with Type 2 Diabetes and Diabetic Kidney Disease: A Pop-ulation-Based Cohort Study in the UK. BMJ Open Diabetes Research & Care, 9, e002146. https://doi.org/10.1136/bmjdrc-2021-002146 |
| [6] | Rajiv, A., Anker, S.D., George, B., et al. (2020) Investigating New Treatment Opportunities for Patients with Chronic Kidney Disease in Type 2 Diabetes: The Role of Finerenone. Nephrology Dialysis Transplantation, 37, 1014-1023. |
| [7] | Bauersachs, J., Frédéric, J. and Toto, R. (2015) Mineralo-corticoid Receptor Activation and Mineralocorticoid Receptor Antagonist Treatment in Cardiac and Renal Diseases. Hy-pertension, 65, 257-263.
https://doi.org/10.1161/HYPERTENSIONAHA.114.04488 |
| [8] | Brown, N.J. (2013) Contribution of Aldosterone to Cardiovascular and Renal Inflammation and Fibrosis. Nature Reviews Nephrology, 9, 459-469. https://doi.org/10.1038/nrneph.2013.110 |
| [9] | Buonafine, M., Bonnard, B. and Jaisser, F. (2018) Mineralocorticoid Receptor and Cardiovascular Disease. American Journal of Hypertension, 31, 1165-1174. https://doi.org/10.1093/ajh/hpy120 |
| [10] | Gomez-Sanchez, E. and Gomez-Sanchez, C.E. (2014) The Multifaceted Mineralocorticoid Receptor. Comprehensive Physiology, 4, 965-994. https://doi.org/10.1002/cphy.c130044 |
| [11] | Ong, G. and Young, M. (2017) Mineralocorticoid Regulation of Cell Function: The Role of Rapid Signalling and Gene Transcription Pathways. Journal of Molecular Endocrinology, 58, R33-R57.
https://doi.org/10.1530/JME-15-0318 |
| [12] | Shibata, S., Nagase, M., Yoshida, S., et al. (2008) Modification of Mineralocorticoid Receptor Function by Rac1 GTPase: Implication in Proteinuric Kidney Disease. Nature Medicine, 14, 1370-1376. https://doi.org/10.1038/nm.1879 |
| [13] | Brem, A. and Gong, R. (2015) Therapeutic Targeting of Aldos-terone: A Novel Approach to the Treatment of Glomerular Disease. Clinical Science, 128, 527-535. https://doi.org/10.1042/CS20140432 |
| [14] | van der Heijden, C., Deinum, J., Joosten, L., et al. (2018) The Mineral-ocorticoid Receptor as a Modulator of Innate Immunity and Atherosclerosis. Cardiovascular Research, 114, 944-953.
https://doi.org/10.1093/cvr/cvy092 |
| [15] | Barrera-Chimal, J., Lima-Posada, I., Bakris, G.L., et al. (2017) Mineral-ocorticoid Receptor Antagonists in Diabetic Kidney Disease—Mechanistic and Therapeutic Effects. Nature Reviews Nephrology, 18, 56-70. |
| [16] | Barrera-Chimal, J., Girerd, S. and Jaisser, F. (2019) Mineralocorticoid Receptor Antago-nists and Kidney Diseases: Pathophysiological Basis. Kidney International, 96, 302-319. https://doi.org/10.1016/j.kint.2019.02.030 |
| [17] | Mi, B., Ying, C., Min, Z., et al. (2017) NLRP3 Inflammasome Ac-tivation Contributes to Aldosterone-Induced Podocyte Injury. American Journal of Physiology-Renal Physiology, 312, F556-F564.
https://doi.org/10.1152/ajprenal.00332.2016 |
| [18] | Shibata, S., Nagase, M., Yoshida, S., et al. (2007) Podocyte as the Target for Aldosterone: Roles of Oxidative Stress and Sgk1. Hypertension, 49, 355-364. https://doi.org/10.1161/01.HYP.0000255636.11931.a2 |
| [19] | Diah, S., Zhang, G.X., Nagai, Y., et al. (2008) Aldos-terone Induces Myofibroblastic Transdifferentiation and Collagen gene Expression through the Rho-Kinase Dependent Signaling Pathway in Rat Mesangial Cells. Experimental Cell Research, 314, 3654-3662. https://doi.org/10.1016/j.yexcr.2008.09.018 |
| [20] | Mathew, J.T., Patni, H., Chaudhary, A.N., et al. (2008) Aldos-terone Induces Mesangial Cell Apoptosis Both in Vivo and in Vitro. American Journal of Physiology-Renal Physiology, 295, 73-81.
https://doi.org/10.1152/ajprenal.00435.2007 |
| [21] | Huang, L.L., Nikolic-Paterson, D.J., et al. (2014) Myeloid Mineralocorticoid Receptor Activation Contributes to Progressive Kidney Disease. Journal of the American Society of Nephrology, 25, 2231-2240.
https://doi.org/10.1681/ASN.2012111094 |
| [22] | Kolkhof, P., Delbeck, M., Kretschmer, A., et al. (2014) Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects from Rat Cardiorenal Injury. Journal of Cardiovascular Pharmacology, 64, 69-78.
https://doi.org/10.1097/FJC.0000000000000091 |
| [23] | Platt, D. and Pauli, H. (1972) Studies on Organ- and Sub-cellular Distribution of 3 H-Spironolactone in Animals. Arzneimittel-Forschung/Drug Research, 22, 1801-1802. |
| [24] | Food and Drug Administration (2021) KERENDIA (Finerenone) Prescribing Information.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215341s000lbl.pdf |
| [25] | Pitt, B., Filippatos, G., Agarwal, R., et al. (2021) Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. The New England Journal of Medicine, 385, 2252-2263. https://doi.org/10.1056/NEJMoa2110956 |
| [26] | Agarwal, R., Joseph, A., Anker, S.D., et al. (2022) Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. Journal of the American Society of Nephrology, 33, 225-237. https://doi.org/10.1681/ASN.2021070942 |
